Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted drug combo shows promise for chinese lung cancer patients with BRAF mutation

NCT ID NCT04452877

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 04, 2025 · Last updated May 08, 2026 · Updated 23 times

Summary

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive NSCLC). The goal was to see if the drugs could shrink tumors. Participants took the drugs until their disease worsened or side effects became too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Harbin, Heilongjiang, 150081, China

  • Novartis Investigative Site

    Changsha, Hunan, 410013, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310022, China

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Guangzhou, 510060, China

  • Novartis Investigative Site

    Shanghai, 200032, China

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG